

Aloke V Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7352510/publications.pdf>

Version: 2024-02-01

156
papers

21,064
citations

34076

52
h-index

9579

142
g-index

161
all docs

161
docs citations

161
times ranked

16017
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 129-138.	0.3	9
2	COBRA PzFâ„¢ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?. <i>Future Cardiology</i> , 2022, 18, 207-217.	0.5	7
3	Sex Differences in Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2022, 24, 23-32.	2.0	14
4	Characterization of Cerebral Embolic Capture Using the SENTINEL Device During Transcatheter Aortic Valve Implantation in Low to Intermediate-Risk Patients: The SENTINEL-LIR Study. <i>Circulation: Cardiovascular Interventions</i> , 2022, , CIRCINTERVENTIONS121011358.	1.4	7
5	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
6	COVID-19â€™Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1066-1075.	2.8	30
7	Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 684-703.	6.1	106
8	ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 542-544.	1.1	27
9	Comparison of Endothelial Barrier Functional Recovery After Implantation of a Novel Biodegradable-Polymer Sirolimus-Eluting Stent in Comparison to Durable- and Biodegradable-Polymer Everolimus-Eluting Stents. <i>Cardiovascular Revascularization Medicine</i> , 2021, 24, 1-10.	0.3	8
10	Co-Registration of Peripheral Atherosclerotic Plaques Assessed by Conventional CT Angiography, MicroCT and Histology in Patients with Chronic Limb Threatening Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 146-154.	0.8	7
11	Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. <i>International Journal of Cardiology</i> , 2021, 327, 52-57.	0.8	11
12	Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes. <i>Atherosclerosis</i> , 2021, 318, 40-42.	0.4	5
13	Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 801-816.	0.6	8
14	Histopathologic analysis of extracted thrombi from deep venous thrombosis and pulmonary embolism: Mechanisms and timing. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1422-1429.	0.7	14
15	Comprehensive Assessment of Human Accessory Renal Artery Periarterial Renal Sympathetic Nerve Distribution. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 304-315.	1.1	13
16	Microthrombi as a Major Cause of Cardiac Injury in COVID-19. <i>Circulation</i> , 2021, 143, 1031-1042.	1.6	196
17	Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1599-1611.	1.2	64
18	Anticytomegalovirus CD4 + T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1459-1473.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Smooth Muscle Cell-Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1724-1737.	1.1	19
20	Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 792-801.e5.	0.2	15
21	Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug-eluting stents. <i>EuroIntervention</i> , 2021, 17, 248-256.	1.4	7
22	Efficacy and safety of cerebral embolic protection systems during transcatheter aortic valve replacement: a review of current clinical findings. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 725-737.	0.6	5
23	<i>APOL1</i> Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2201-2214.	1.1	8
24	Response by Pellegrini et al to Letter Regarding Article, "Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study". <i>Circulation</i> , 2021, 144, e158-e159.	1.6	4
25	Endothelial Recovery in Bare Metal Stents and Drug-Eluting Stents on a Single-Cell Level. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2277-2292.	1.1	7
26	Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. <i>International Journal of Cardiology</i> , 2021, 338, 42-49.	0.8	3
27	Paradise, "Ultrasound Renal Denervation System for the treatment of hypertension. <i>Future Cardiology</i> , 2021, 17, 931-944.	0.5	1
28	Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 314-325.	1.2	177
29	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
30	Overcoming challenges in refining the current generation of coronary stents. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1013-1028.	0.6	1
31	Drug-eluting coronary stents: insights from preclinical and pathology studies. <i>Nature Reviews Cardiology</i> , 2020, 17, 37-51.	6.1	150
32	Diversity of macrophage phenotypes and responses in atherosclerosis. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1919-1932.	2.4	118
33	What atherosclerosis findings can CT see in sudden coronary death: Plaque rupture versus plaque erosion. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 214-218.	0.7	10
34	Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. <i>European Heart Journal</i> , 2020, 41, 786-796.	1.0	41
35	Imaging Human Platelet Adhesion and Albumin Retention to Coronary Stents in Real Time. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 245-248.	0.3	0
36	Cause of Stent Failure in Patients on Hemodialysis. <i>Journal of the American Heart Association</i> , 2020, 9, e018621.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 2020, 127, 1552-1565.	2.0	60
38	Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. <i>Atherosclerosis</i> , 2020, 306, 85-95.	0.4	94
39	Microthrombi and ST-Segment Elevation Myocardial Infarction in COVID-19. <i>Circulation</i> , 2020, 142, 804-809.	1.6	68
40	Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1226-1243.	1.2	140
41	Healthy Strut Coverage After Coronary Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008869.	1.4	14
42	Advances in mammalian target of rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease. <i>Future Medicinal Chemistry</i> , 2020, 12, 1181-1195.	1.1	2
43	Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2020, 17, 189-200.	1.4	5
44	Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 418-427.	1.1	8
45	Calcification in human vessels and valves: from pathological point of view. <i>AIMS Molecular Science</i> , 2020, 7, 183-210.	0.3	6
46	Basic Pathology of Arterial and Valvular Calcification in Humans. <i>Contemporary Cardiology</i> , 2020, , 13-45.	0.0	0
47	Pathology of stent implantation in internal mammary artery. <i>Cardiovascular Intervention and Therapeutics</i> , 2019, 34, 1-8.	1.2	4
48	New insights into the role of iron in inflammation and atherosclerosis. <i>EBioMedicine</i> , 2019, 47, 598-606.	2.7	96
49	Types and pathology of vascular calcification. , 2019, , 1-25.		0
50	Evaluation and Management of the Vulnerable Plaque. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	3
51	Calcified Plaques in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 531-540.	1.1	92
52	IN.PACT TM ; Admiral TM ; drug-coated balloons in peripheral artery disease: current perspectives. <i>Medical Devices: Evidence and Research</i> , 2019, Volume 12, 53-64.	0.4	8
53	Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 103-109.	0.2	38
54	Histopathologic Characterization of Peripheral Arteries in Subjects With Abundant Risk Factors. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1501-1513.	2.3	53

#	ARTICLE	IF	CITATIONS
55	Fully bioresorbable vascular scaffolds: lessons learned and future directions. <i>Nature Reviews Cardiology</i> , 2019, 16, 286-304.	6.1	143
56	Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. <i>Journal of Clinical Investigation</i> , 2019, 130, 295-314.	3.9	45
57	What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology?. <i>Heart International</i> , 2019, 13, 15.	0.4	12
58	Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. <i>EuroIntervention</i> , 2019, 14, 1685-1693.	1.4	27
59	Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy. <i>EuroIntervention</i> , 2019, 15, e342-e353.	1.4	23
60	Coronary Artery Calcification and Progression. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 127-142.	2.3	282
61	A new category stent with novel polyphosphazene surface modification. <i>Future Cardiology</i> , 2018, 14, 225-235.	0.5	11
62	The Authors Reply. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 518.	2.3	0
63	The Stress of Plaque Prognostication. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 472-475.	2.3	2
64	Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilatation in a Healthy Swine Model. <i>Journal of Endovascular Therapy</i> , 2018, 25, 118-126.	0.8	15
65	Coronary artery calcification. <i>Current Opinion in Cardiology</i> , 2018, 33, 645-652.	0.8	15
66	Micro-Computed Tomography Demonstration of Multiple Plaque Ruptures in a Single Individual Presenting With Sudden Cardiac Death. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e008331.	1.3	7
67	Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View. <i>Bioengineering</i> , 2018, 5, 71.	1.6	66
68	Pathological mechanisms of left main stent failure. <i>International Journal of Cardiology</i> , 2018, 263, 9-16.	0.8	20
69	Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2217-2224.	1.1	30
70	Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1041-1049.e3.	0.2	22
71	Pathologic intimal thickening: Are we any closer to understand early transitional plaques that lead to symptomatic disease?. <i>Atherosclerosis</i> , 2018, 274, 227-229.	0.4	9
72	Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution. <i>Expert Review of Medical Devices</i> , 2018, 15, 665-682.	1.4	9

#	ARTICLE	IF	CITATIONS
73	An uncommon but important cause of stent thrombosis: Kounis syndrome. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 818-819.	0.3	2
74	CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. <i>Journal of Clinical Investigation</i> , 2018, 128, 1106-1124.	3.9	209
75	Nonatherosclerotic Vascular Disease in Women. <i>Texas Heart Institute Journal</i> , 2018, 45, 233-235.	0.1	2
76	Covering our tracks “optical coherence tomography to assess vascular healing. <i>EuroIntervention</i> , 2018, 14, e1247-e1251.	1.4	5
77	9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 160-167.	1.1	35
78	Pathology of Chronic Total Occlusion in Bare-Metal Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 367-378.	1.1	16
79	Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 191-204.	1.1	352
80	Metallic Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1175-1177.	1.1	12
81	Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
82	Linking Hemorrhage, Angiogenesis, Macrophages, and Iron Metabolism in Atherosclerotic Vascular Diseases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, e33-e39.	1.1	38
83	Revisiting the role of durable polymers in cardiovascular devices. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 835-846.	0.6	15
84	Endothelial Barrier Protein Expression in Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2375-2387.	1.1	27
85	Avances reveladores sobre la trombosis del stent. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 1036-1038.	0.6	0
86	Bioresorbable vascular scaffolds. <i>Coronary Artery Disease</i> , 2017, 28, 533-538.	0.3	5
87	Catastrophic Consequence of Gauze During Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e141-e142.	1.1	0
88	Illuminating Insights Into Stent Thrombosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1036-1038.	0.4	0
89	Clinical implications of blood-material interaction and drug eluting stent polymers in review. <i>Expert Review of Medical Devices</i> , 2017, 14, 707-716.	1.4	14
90	Very Late Pathological Responses to Cobalt-Chromium Everolimus-Eluting, Stainless Steel Sirolimus-Eluting, and Cobalt-Chromium Bare Metal Stents in Humans. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	34

#	ARTICLE	IF	CITATIONS
91	Calcified Nodule. JACC: Cardiovascular Interventions, 2016, 9, e125-e126.	1.1	44
92	Stenting of Spontaneous Coronary Artery Dissection From a Pathological Point of View. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	9
93	Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology, 2016, 222, 217-225.	0.8	24
94	Histopathological Differential Diagnosis of Optical Coherence Tomographic Image Interpretation After Stenting. JACC: Cardiovascular Interventions, 2016, 9, 2511-2523.	1.1	50
95	Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?. Lancet, The, 2016, 388, 2567-2568.	6.3	0
96	The clinical challenge of disappearing stents. Lancet, The, 2016, 387, 510-512.	6.3	11
97	Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nature Reviews Cardiology, 2016, 13, 79-98.	6.1	399
98	Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacological Research, 2015, 93, 22-27.	3.1	45
99	Illuminating Culprit Plaque Histology by Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2015, 8, 1177-1179.	1.1	0
100	Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: A pathology study. Atherosclerosis, 2015, 241, 772-782.	0.4	151
101	Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques. Atherosclerosis, 2015, 241, 692-700.	0.4	29
102	Embolic Myocardial Infarction as a Consequence of Atrial Fibrillation. Circulation, 2015, 132, 223-226.	1.6	31
103	Eosinophils. Coronary Artery Disease, 2015, 26, 99-100.	0.3	3
104	CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nature Communications, 2015, 6, 7792.	5.8	75
105	Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model. Circulation: Cardiovascular Interventions, 2014, 7, 526-532.	1.4	11
106	The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. Frontiers in Pharmacology, 2014, 5, 195.	1.6	54
107	Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans. Circulation, 2014, 129, 211-223.	1.6	422
108	2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nature Medicine, 2014, 20, 215-219.	15.2	159

#	ARTICLE	IF	CITATIONS
109	Causes of Early Stent Thrombosis in Patients Presenting With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2510-2520.	1.2	102
110	Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. <i>European Heart Journal</i> , 2014, 35, 1683-1693.	1.0	119
111	Clinical and Angiographic Results After Hybrid Coronary Revascularization. <i>Annals of Thoracic Surgery</i> , 2014, 97, 484-490.	0.7	51
112	Early clinical and angiographic outcomes after robotic-assisted coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 179-185.	0.4	83
113	Update on acute coronary syndromes: the pathologists' view. <i>European Heart Journal</i> , 2013, 34, 719-728.	1.0	849
114	Do vulnerable and ruptured plaques hide in heavily calcified arteries?. <i>Atherosclerosis</i> , 2013, 229, 34-37.	0.4	47
115	Metformin Impairs Vascular Endothelial Recovery After Stent Placement in the Setting of Locally Eluted Mammalian Target of Rapamycin Inhibitors Via S6 Kinase-Dependent Inhibition of Cell Proliferation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 971-980.	1.2	35
116	Histopathologic Characteristics of Atherosclerotic Coronary Disease and Implications of the Findings for the Invasive and Noninvasive Detection of Vulnerable Plaques. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1041-1051.	1.2	438
117	Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. <i>European Heart Journal</i> , 2013, 34, 3304-3313.	1.0	100
118	Computational Fluid Dynamics Simulations of Hemodynamics in Plaque Erosion. <i>Cardiovascular Engineering and Technology</i> , 2013, 4, 464-473.	0.7	20
119	Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C- β Activation and Disruption of the p120 ^{cas} -Vascular Endothelial Cadherin Interaction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2425-2431.	1.1	53
120	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ</i> , The, 2013, 347, f6530-f6530.	3.0	194
121	Pharmacological Suppression of Hepcidin Increases Macrophage Cholesterol Efflux and Reduces Foam Cell Formation and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 299-307.	1.1	129
122	Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell Formation in Human Atherosclerotic Plaques. <i>Journal of the American College of Cardiology</i> , 2012, 59, 166-177.	1.2	265
123	Pathology of Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Bypass Graft Lesions. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 666-674.	1.1	54
124	Ex Vivo Assessment of Vascular Response to Coronary Stents by Optical Frequency Domain Imaging. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 71-82.	2.3	113
125	Lessons Learned from Robotic-Assisted Coronary Artery Bypass Surgery: Risk Factors for Conversion to Median Sternotomy. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2012, 7, 323-327.	0.4	11
126	The importance of the endothelium in atherothrombosis and coronary stenting. <i>Nature Reviews Cardiology</i> , 2012, 9, 439-453.	6.1	314

#	ARTICLE	IF	CITATIONS
127	Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 390-398.	1.2	283
128	The Pathology of Neoatherosclerosis in Human Coronary Implants. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1314-1322.	1.2	834
129	Concept of Vulnerable/Unstable Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1282-1292.	1.1	982
130	Pathological Findings at Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1679-1687.	1.2	228
131	Pharmacotherapy of coronary atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1587-1603.	0.9	26
132	Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor β Agonists. <i>Circulation Research</i> , 2009, 105, 1003-1012.	2.0	24
133	Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. <i>American Heart Journal</i> , 2009, 157, 383.e1-383.e8.	1.2	9
134	Incidence and Predictors of Drug-Eluting Stent Fracture in Human Coronary Artery. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1924-1931.	1.2	229
135	Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 535-544.	1.1	48
136	Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2008, 52, 333-342.	1.2	594
137	Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients. <i>Circulation</i> , 2008, 118, 1138-1145.	1.6	818
138	Drug-eluting stent safety: findings from preclinical studies. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1379-1391.	0.6	72
139	Herman Kalman Gold, MD. <i>Circulation</i> , 2008, 118, 1212-1213.	1.6	0
140	Total erythrocyte membrane cholesterol: a marker of plaque instability?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 646-647.	3.3	0
141	Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 491-502.	3.3	104
142	Controversies Surrounding the Use of Drug-Eluting Stents. <i>The American Heart Hospital Journal</i> , 2007, 5, 141-145.	0.2	0
143	Pathological Correlates of Late Drug-Eluting Stent Thrombosis. <i>Circulation</i> , 2007, 115, 2435-2441.	1.6	1,200
144	Response to Letter Regarding Article, "Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization". <i>Circulation</i> , 2007, 116, .	1.6	2

#	ARTICLE	IF	CITATIONS
145	Vascular Responses to Drug Eluting Stents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1500-1510.	1.1	826
146	Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 2007, 50, 940-949.	1.2	326
147	Pathology of drug-eluting stents: implications for coronary intervention. <i>Indian Heart Journal</i> , 2007, 59, B41-9.	0.2	1
148	Pathology of Drug-Eluting Stents in Humans. <i>Journal of the American College of Cardiology</i> , 2006, 48, 193-202.	1.2	2,537
149	Everolimus eluting stents: beyond targeting restenosis!. <i>EuroIntervention</i> , 2006, 2, 277-9.	1.4	1
150	Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents. <i>Circulation</i> , 2005, 112, 270-278.	1.6	560
151	Atherosclerotic Plaque Progression and Vulnerability to Rupture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2054-2061.	1.1	1,197
152	Drug-eluting stents for diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2005, 45, 479-483.	1.2	45
153	Intraplaque Hemorrhage and Progression of Coronary Atheroma. <i>New England Journal of Medicine</i> , 2003, 349, 2316-2325.	13.9	1,319
154	Isolated Right Ventricular Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1636-1636.	13.9	32
155	The thin-cap fibroatheroma: a type of vulnerable plaque: The major precursor lesion to acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2001, 16, 285-292.	0.8	584
156	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. <i>US Cardiology Review</i> , 0, 16, .	0.5	4